Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Obinutuzumab vs Chlorambucil + Obinutuzumab in Untreated CLL
NCT01980875Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Apr 2015; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01980875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01980875.